Led · Equity · Feb 2026

Founded in 2021 as a spin-out from Cardiff University, MeOmics Precision Medicine uses induced pluripotent stem cell technology to create patient-derived models that reveal the underlying biological sub-types of complex mental illnesses such as schizophrenia. By pairing these cellular models with data analytics, the company enables pharmaceutical partners to screen compounds against biologically matched patient groups, lowering clinical failure rates and reducing harmful side-effects from mis-targeted drugs. The platform aims to replicate in psychiatry the precision-medicine advances already common in oncology. MeOmics has been supported by an Innovate UK grant and earlier backing from St Andrew’s Healthcare. Its newest funding brings in £300,000 of equity and follows a £25,000 Smart Flexible Innovation Support grant from the Welsh Government. The fresh capital will be used to optimise the platform, expand data generation capabilities, and hire additional technical staff as the firm moves toward commercialisation.

Participated · Crowdfunding · Jan 2026

PlantSea has created a natural polymer membrane derived from seaweed that can either dissolve in water or fully biodegrade in compost, while still allowing manufacturers to heat-seal or vacuum-form the material. The technology targets water-soluble plastics used in laundry capsules and similar products, positioning itself as a cost-competitive, drop-in, plastic-free alternative across home-care, food, pharmaceutical and broader industrial applications. Successful paid pilots have already generated early revenue and demonstrated production viability for key clients. To date, the company has secured a £1 million Innovate UK grant and previously closed a £700 k pre-seed equity round. The latest crowdfunding raise values the business at a £6 million pre-money figure and is intended to accelerate scale-up, bolster commercial partnerships, expand headcount and obtain critical certifications. Management aims to convert pilot programmes into longer-term offtake contracts, thereby reducing future capital requirements. Additional investor interest generated by the campaign could further extend the current financing.

Participated · Equity · Apr 2024

PeppercornAI develops conversational AI technology for the insurance sector, positioning its product to lower operating costs and improve customer experience. The company launched its SaaS platform Pipr last year to support the motor industry amid rising cost pressures. Led by CEO Nigel Lombard and based in the Greater Cardiff Area, Wales, UK, PeppercornAI targets B2B demand through its conversational offerings. The firm intends to use its latest funding to further develop its conversational AI technology and support its pipeline of B2B customers. Financially, PeppercornAI has completed multiple financings, including a recent £3.25M round and a prior £1.8M seed in April 2022 from EHE Capital. The company’s product and go-to-market focus remain centered on servicing insurers and motor-industry clients under cost pressure.

Participated · Equity · Apr 2016

Jellagen develops Collagen Type 0, a jellyfish-derived collagen biomaterial sourced from Rhizostoma pulmo for use in medical devices and culture applications. The jellyfish-derived material is intended to avoid disease and virus-transfer risks associated with mammalian collagens. The company plans to accelerate medical development of Collagen Type 0 and advance its program toward human trials and regulatory filing. Jellagen has established development collaborations with research organisations including the Mayo Clinic in the US and partners in Europe to investigate and corroborate its findings. The company is led by CEO Thomas‑Paul Descamps and bases its work on research from Professor Andrew Mearns Spragg. Jellagen is based in Cardiff, Wales, UK, and recently closed an £8.7M Series A to support its clinical and regulatory programs. Jellagen develops advanced collagen biomaterials sourced from a single species of jellyfish, which the company says avoids mammalian disease risks and offers superior healing benefits. The company has an established range of products for the cell culture reagent market and has completed pre-clinical datasets in proven animal models supporting use in human tissue reconstruction, diabetic wound healing and other medical applications. Jellagen has conducted collaborations with leading research organisations in the US and Europe and notes recent data have been published in peer-reviewed scientific articles. The company plans to develop and partner pipeline products aimed at tissue reconstruction, diabetic wound care management and rare skin applications. Jellagen intends to explore development and licensing arrangements with potential pharma and medical-device partners to commercialize its findings. The business was founded in 2015 and is based in Cardiff, Wales. Jellagen is a commercial manufacturer of jellyfish collagen based in Cardiff, Wales. Its jellyfish collagen is intended for wound care and regenerative medicine, and the company's first product range comprises cell culture reagents used to grow stem cells. Jellagen also plans to produce medical devices engineered around jellyfish collagen. Founded in 2013 by Professor Andrew Mearns Spragg (CEO), the firm is advancing commercial applications of its collagen. The company received funding to accelerate sales of its jellyfish-based medicine, grow its specialist management team and strengthen its intellectual property portfolio. Jellagen exploits jellyfish to provide next‑generation collagen biomaterials for application in 3D cell culture, in vitro diagnostics (including research‑level regenerative medicine R&D) and medical devices. The company completed a further £1.53m in equity funding to support its operations and growth. Jellagen intends to use the funds to expand and increase its collagen processing capacity and to establish a Quality Management System. It plans to recruit up to six new staff over the next two years and to strengthen and build its IP portfolio. The company will also allocate capital to business development and marketing activities aimed at increasing sales. Jellagen was founded in August 2013 by Dr Andrew Mearns Spragg and is based in Pembroke Dock, UK.